Table 1 Patient and transplant characteristics.

From: Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings

 

FTBI/ETOP (N = 205)

FTBI/FLU (N = 64)

Total (N = 269)

p value

Age at HSCT, years

   

0.55

 Median (Range)

37 (19-59)

33 (9-68)

37 (9-68)

 

Recipient sex

   

0.14

 Male

127 (62%)

33 (51.6%)

160 (59.5%)

 

 Female

78 (38%)

31 (48.4%)

109 (40.5%)

 

Race/ethnicity

   

0.0095

 White

57 (27.8%)

9 (14.1%)

66 (24.5%)

 

 African American

2 (1%)

0 (0%)

2 (0.7%)

 

 Asian

28 (13.7%)

4 (6.3%)

32 (11.9%)

 

 Hispanic

113 (55.1%)

47 (73.4%)

160 (59.5%)

 

 Native

4 (2%)

1 (1.6%)

5 (1.9%)

 

 Not reported

1 (0.5%)

3 (4.7%)

4 (1.5%)

 

Karnofsky performance status %

   

0.19

 80–100

189 (92.2%)

62 (96.9%)

251 (93.3%)

 

 ≤70

16 (7.8%)

2 (3.1%)

18 (6.7%)

 

HCT comorbidity index

   

0.0002

 0

77 (37.6%)

7 (10.9%)

84 (31.2%)

 

 1–2

70 (34.1%)

28 (43.8%)

98 (36.4%)

 

 ≥3

58 (28.3%)

29 (45.3%)

87 (32.3%)

 

Disease type

   

0.13

 B-ALL

174 (84.9%)

59 (92.2%)

233 (86.6%)

 

 T-ALL

31 (15.1%)

5 (7.8%)

36 (13.4%)

 

Disease status

   

0.045

 CR1

168 (82%)

45 (70.3%)

213 (79.2%)

 

 CR2+

37 (18%)

19 (29.7%)

56 (20.8%)

 

MRD status

   

0.66

 MRD+

42 (31.3%)

16 (28.1%)

58 (21.6%)

 

 MRD-

92 (68.7%)

41 (71.9%)

133 (49.4%)

 

 NA

71

7

78 (29%)

 

Cytogenetic risk

   

0.92

 Standard

50 (24.4%)

16 (25%)

66 (24.5%)

 

 High

155 (75.6%)

48 (75%)

203 (75.5%)

 

Philadelphia status

   

0.82

 Ph+

77 (37.6%)

25 (39.1%)

102 (37.9%)

 

 Ph-

107 (52.2%)

31 (48.4%)

138 (51.3%)

 

 Ph-like

21 (10.2%)

8 (12.5%)

29 (10.8%)

 

Female donor to male recipient

   

0.18

 Yes

52 (25.4%)

11 (17.2%)

63 (23.4%)

 

 No

153 (74.6%)

53 (82.8%)

206 (76.6%)

 

Donor age

   

0.20

 Median (Range)

33 (11-62)

31 (14-65)

32 (11-65)

 

 Interquartile range

27, 43

23, 42

26, 43

 

Donor Type

   

<0.0001

 MUD

192 (93.7%)

4 (6.3%)

196 (72.9%)

 

 MMUD

13 (6.3%)

13 (20.3%)

26 (9.7%)

 

 Haplo

0 (0%)

47 (73.4%)

47 (17.5%)

 

ABO blood group compatibility

   

0.31

 ABO compatible

134 (65.4%)

42 (65.6%)

176 (65.4%)

 

 Minor mismatch (donor is O)

27 (13.2%)

5 (7.8%)

32 (11.9%)

 

 Major mismatch (Recipient is O)

31 (15.1%)

9 (14.1%)

40 (14.9%)

 

 Bidirectional (None are O)

13 (6.3%)

8 (12.5%)

21 (7.8%)

 

Donor/Recipient CMV serostatus

   

0.34

 D-/R-

19 (9.3%)

6 (9.4%)

25 (9.3%)

 

 D-/R+

53 (25.9%)

11 (17.2%)

64 (23.8%)

 

 D+/R-

10 (4.9%)

6 (9.4%)

16 (5.9%)

 

 D+/R+

123 (60%)

41 (64.1%)

164 (61%)

 

HCT period

    

 2010-2014

83 (40.5%)

0 (0%)

83 (30.9%)

 

 2015-2020

122 (59.5%)

64 (100%)

186 (69.1%)

 

GVHD prophylaxis

    

 Cyclophosphamide/Tacrolimus/MMF

0 (0%)

64 (100%)

64 (23.8%)

 

 Tacrolimus/Sirolimus

205 (100%)

0 (0%)

205 (76.2%)

 
Back to article page